NIKKEI 225
40,425.37 +350.68 (+0.88%) HANG SENG
17,816.21 +47.07 (+0.26%) CRUDE OIL
83.12 +0.31 (+0.37%) GOLD FUTURES
2,336.40 +3.00 (+0.13%) DOW
39,331.85 +162.33 (+0.41%) Bitcoin GBP
48,298.62 -1,316.92 (-2.65%)
CRBU Jan 2025 2.500 call
| Previous close | 0.4000 |
| Open | 0.3000 |
| Bid | 0.3000 |
| Ask | 0.7000 |
| Strike | 2.50 |
| Expiry date | 2025-01-17 |
| Day's range | 0.3000 - 0.3500 |
| Contract range | N/A |
| Volume | |
| Open interest | 496 |
GlobeNewswireCaribou Biosciences Presents Encouraging Clinical Data from CB-010 ANTLER Phase 1 Trial in Second-line LBCL Patients at the 2024 American Society of Clinical Oncology (ASCO) Annual Meeting
-- CB-010 allogeneic CAR-T cell therapy with partial HLA matching has potential to rival efficacy and safety profile of approved autologous CAR-T cell therapies -- -- 14.4 months median PFS in ANTLER patients with partial HLA matching (≥4 alleles) -- -- Plan to enroll ~20 additional 2L LBCL patients in ANTLER to confirm that partial HLA matching improves patient outcomes; initial data expected in H1 2025 -- -- Caribou expects to initiate a pivotal trial for CB-010 in H2 2025, upon confirmation o
GlobeNewswireCaribou Biosciences to Host KOL Discussion with Webcast from the 2024 ASCO Annual Meeting and Participate in Upcoming Investor Conferences
BERKELEY, Calif., May 30, 2024 (GLOBE NEWSWIRE) -- Caribou Biosciences, Inc. (Nasdaq: CRBU), a leading clinical-stage CRISPR genome-editing biopharmaceutical company, today announced the company’s participation in the following event and investor conferences: • Caribou’s webcast of KOL discussion from 2024 American Society of Clinical Oncology (ASCO) Annual MeetingJune 2, 2024, CB-010 ANTLER Phase 1 clinical trial data in r/r B-NHL to be shared in a press release at 6:00 pm CDT followed by a liv
Simply Wall St.Caribou Biosciences, Inc. (NASDAQ:CRBU) Analysts Are Cutting Their Estimates: Here's What You Need To Know
Caribou Biosciences, Inc. ( NASDAQ:CRBU ) shareholders are probably feeling a little disappointed, since its shares...
